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ABSTRACT
Background: Huntington’s disease is caused by expan-
sion of a polyglutamine tract found in the amino-terminal
of the ubiquitously expressed protein huntingtin. Well
studied in its mutant form, huntingtin has a wide variety
of normal functions, loss of which may also contribute to
disease progression. Widespread transcriptional dysfunc-
tion occurs in brains of Huntington’s disease patients and
in transgenic mouse and cell models of Huntington’s
disease.
Methods: To identify new transcriptional pathways
altered by the normal and/or abnormal function of
huntingtin, we probed several nuclear receptors, normally
expressed in the brain, for binding to huntingtin in its
mutant and wild-type forms.
Results: Wild-type huntingtin could bind to a number of
nuclear receptors; LXRa, PPARc, VDR and TRa1. Over-
expression of huntingtin activated, while knockout of
huntingtin decreased, LXR mediated transcription of a
reporter gene. Loss of huntingtin also decreased
expression of the LXR target gene, ABCA1. In vivo,
huntingtin deficient zebrafish had a severe phenotype and
reduced expression of LXR regulated genes. An LXR
agonist was able to partially rescue the phenotype and
the expression of LXR target genes in huntingtin deficient
zebrafish during early development.
Conclusion: Our data suggest a novel function for wild-
type huntingtin as a co-factor of LXR. However, this
activity is lost by mutant huntingtin that only interacts
weakly with LXR.
Huntington’s disease (HD) is a devastating auto-
somal dominant neurodegenerative disease char-
acterised by motor, psychiatric and cognitive
dysfunctions. HD is caused by an abnormal
expansion of a polyglutamine tract located in the
N-terminus of a ubiquitously expressed protein
called huntingtin.
1 Huntingtin polyglutamine
tracts in the normal population have up to 35
CAG repeats while those of HD patients are
expanded to 36 or more CAG repeats.
2 Genetic
data in humans and transgenic animal models
suggest that polyglutamine expansions confer a
deleterious gain-of-function on the target proteins.
3
However, this does not preclude the possibility
that the severity of HD may be modified by loss-
of-function effects.
4 Huntingtin is present in the
nucleus, suggesting it may play a role in nuclear
events.
5 Single candidate gene and unbiased micro-
array approaches have clearly demonstrated that
transcription of numerous genes is dysregulated in
human HD brain
6 and in transgenic mouse and cell
models of HD.
7 The promoter motifs of genes
downregulated in HD cell models suggested defects
in transcription mediated through cAMP response
element binding (CREB) protein, retinoic acid
receptor (RAR), and specificity protein-1 (Sp1).
89
Both wild-type and mutant huntingtin bind to a
number of transcription factors, including Sp1 and
CREB protein. In some cases, this interaction can
be strengthened by expanded polyglutamine.
10–12
Mechanistically, huntingtin appears to regulate
transcription both as a normal function and as a
deleterious gain-of-function upon expansion of its
polyglutamine tract. Although transcription fac-
tors can be localised to nuclear inclusions formed
by mutant huntingtin,
12–14 it is unclear whether
mutant huntingtin perturbs transcription by sim-
ply sequestering transcription factors in aggre-
gates.
15 Soluble mutant huntingtin may act to
disrupt transcription factor binding to DNA.
10 11
Important work has revealed a role for wild-type
huntingtin in HD where loss of function of
huntingtin contributes to the severity of the
disease by disrupting transcription of neuronal
genes. Wild-type but not mutant huntingtin
stimulated transcription of the gene encoding brain
derived neurotrophic factor (BDNF).
4 This effect
occurs through cytoplasmic sequestering of repres-
sor element-1 transcription factor/neuron restric-
tive factor (REST/NRSF) that can bind to the
promoter of the BDNF gene to repress its
transcription. Mutant huntingtin binds less avidly
to REST/NRSF allowing it to enter the nucleus and
repress BDNF gene expression.
16 Polyglutamine
expansion may result in both a loss and a gain of
specific functions of a protein, as has been
elegantly demonstrated for ATX1, where expan-
sion of the CAG repeat differentially affects its
function in the context of different endogenous
protein complexes.
17
To elucidate new transcriptional pathways
regulated by huntingtin, we tested several nuclear
receptors (NRs), normally expressed in the brain,
for their ability to interact with the N-terminal
fragment of huntingtin (amino acids 1–588) with a
normal (17Q) or expanded (138Q) polyglutamine
repeat. Nuclear receptors are of particular interest
since they control a wide range of physiological
processes and are highly expressed in the brain;
94% of all nuclear receptors are found endogen-
ously in neurons.
18 In this study, we found wild-
type huntingtin could bind to a number of nuclear
receptors including: LXRa, peroxisome proliferator-
activated receptor-c (PPARc), vitamin D receptor
(VDR), and thyroid hormone receptor-a1 (TRa1).
Recent work describes the disruption of cholesterol
homeostasis in HD.
19 The two LXRs, LXRa and
LXRb, are recognised to be central regulators of
cholesterol metabolism in mammals. Both LXRs
activate target genes by binding to response
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the retinoid X receptor (RXR). Oxysterols and intermediates of
the biosynthetic cholesterol pathway have been identified as the
natural ligands for LXR (reviewed by Wojcicka et al
20). We found
LXR bound to wild-type huntingtin via its ligand binding
domain (LBD). Over-expression of huntingtin activates LXR
mediated transcription and knockout of huntingtin decreases
LXR mediated transcription. Furthermore, knockout of hun-
tingtin decreases expression of ABCA1, a key downstream
target gene regulated by LXR. An agonist of LXR partially
rescues the phenotype observed in huntingtin deficient zebra-
fish. These data suggest that huntingtin can regulate LXR
mediated transcription and may play a general role as a co-
factor of nuclear receptors. LXR transcriptional deficiency may
contribute to the phenotypes of huntingtin defects in vivo.
METHODS
Expression constructs
cDNAs encoding human LXRa, PPARc, VDR, TRa1 and RXRa
were polymerase chain reaction (PCR) cloned into the
pcDNA3.1Myc-His vector using the following restriction sites
respectively; BamHI/XhoI, KpnI/XhoI, BamHI/XhoI, BamHI/
NotI and EcoRI/XhoI. GST tagged LXRa was then generated by
subcloning into BamHI/XhoI digested pGEX-6P-1. His tagged
huntingtin 190 was generated by PCR cloning into NdeI/BamHI
digested pET15b. Leucine to alanine point mutations were
generated using the Quikchange (Stratagene, La Jolle,
California, USA) site directed mutagenesis kit. All constructs
were verified by DNA sequencing.
Immunoprecipitations
SK-N-SH or COS-7 cells were plated in 10 cm dishes and
transfected with 2 mg Myc tagged NR constructs and 2 mg FLAG
tagged Htt constructs as specified in the text, using either
Lipofectamine Plus (Invitrogen, Paisley, UK) or Lipofectamine
(Invitrogen) (20 ml Plus and 10 ml lipofectamine per dish),
respectively. The medium was changed after 4 h. Following 24
or 48 h incubation, respectively, cells were lysed in IP buffer
(20 mM Tris pH7.5, 150 mM NaCl, 0.5% NP40, 2 mM MgCl2,
protease inhibitors) and protein assays performed (Dc protein
assay, Bio-rad, Hemel Hempstead, UK). 100 mg total protein
was incubated with rabbit anti-Myc antibody overnight on a
rotating shaker at 4uC. A volume of 15 ml protein A magnetic
beads (Invitrogen) per IP was washed once in IP buffer,
resuspended to 15 ml then added to the lysate/antibody mix
and incubated for a further 1 h. The beads and proteins bound
were then separated from the remaining lysate using a magnet
and were washed three times in IP buffer. The bound proteins
were eluted in 100 mM glycine pH2.5, resolved by SDS-PAGE
and transferred to PVDF membrane (Anachem, Luton, UK).
Membranes were probed with anti-huntingtin monoclonal
antibody (Chemicon, Millipare, Watford, UK) or anti-FLAG
M2 antibody (Sigma, St Louis, Missouri, USA) to detect
huntingtin immunoprecipitated by NRs.
Luciferase assays
HEK cells or ES cells were plated on poly-D-lysine or gelatin
coated 96 well plates. HEK cells were transfected with 1.7 ng
LXR, 1.7 ng LXR response element (LXRE) or empty luciferase
reporter, 5 ng b-galactosidase, 51 ng Htt or empty vector, 0.6 ml
Plus reagent and 0.3 ml lipofectamine reagent per well. ES cells
were transfected with 40 ng LXR, 40 ng LXRE, 120 ng b-
galactosidase and 0.5 ml lipofectamine 2000 per well. The medium
was changed after 4 h incubation. Following 24 h incubation,
luciferase assays were performed. Cells were treated overnight
with 50 nM of the LXR agonist, TO901317, as indicated.
Q-PCR
ES cells were incubated overnight (18 h) in the presence or
absence of 25 nM LXR agonist, GW683965A. Zebrafish were
injected with huntingtin morpholino and treated with LXR
agonist as described below. RNA was prepared from ES cells or
72 hpf zebrafish using the RNAeasy kit (Qiagen, Crawley, UK).
Following DNase treatment (Invitrogen), 1 mg RNA was reverse
transcribed to make cDNA using the Superscript III kit
(Invitrogen). Q-PCR was performed using 8 ml cDNA, 375 nM
final concentration of each primer and 2X SYBR green
mastermix (ABI systems, Warrington, UK) in a total of 20 ml
per well on an ABI 7900 fast Q-PCR machine. Cts were
normalised to a cDNA standard curve and to the housekeeping
gene GAPDH or b-actin. Primers used were: ABCG1 59-
CAGGGTGGAAGAACCGTCAT -39 and 59-A A G C T T G T C -
GAAGAGCTCGAA-39,C Y P 7 A 15 9- GCAGGCGTGCCAATGTG
-39 and 59- CCAACTGCTCCCTTGTCAGT-39,L X R5 9- GAGAT-
TCTCAGTCAAACGGACTTG-39 and 59- TGATGTCGTTGGA-
TTCCATGA-39,F A S N5 9- CGCTTGTCCTACTTCTTTGAT-
TTCA-39 and 59- TTCCAGTGCCAGCAGACTAGAG-39,A C C
59- GTGGAGAAGGCCATCAAAAA-39 and 59- TGCTGAA-
ACTGAACCTCCACT-39, b-actin 59- TGCCCCTCGTGCTG-
TTTT-39 and 59- TCTGTCCCATGCCAACCAT-39,G A P D H
59- TGTGTCCGTCGTGGATCTGA-39 and 59- CCTGCTTCA-
CCACCTTCTTGAT-39,A B C A 15 9- AAGGGTTTCTTTGCT-
CAGATTGTC -39 and 59- TGCCAAAGGGTGGCACA-39
GST and His tagged protein purification and GST pulldowns
GST and His tagged proteins were purified from BL21
Escherichia coli; 200 ml cultures (OD 0.8) were induced with
1 mM IPTG for 1 h, pelleted and resuspended in 20 ml GST
(10 mM KCl, 1 mM DTT, protease inhibitors in PBS) or His
binding buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM
imidazole). Lysozyme was added to a final concentration of
1 mg/ml and the cell suspension incubated for 15 mins at room
temperature. The suspension was then lysed by five freeze-thaw
cycles and NP40 added to a final concentration of 0.5%.
Following 30 mins incubation the lysate was sonicated (three
bursts for 30 s each) using a probe sonicator and insoluble
material removed by centrifugation at 10 000 rpm for 20 mins.
GST or His tagged proteins were batch purified with 0.5 ml
GST-sepharose (Amersham Biosciences) or 0.5 ml Ni-NTA
agarose (Qiagen), washed four times in GST binding buffer or
His washing buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM
imidazole) and eluted with 10 mM glutathione or 250 mM
imidazole. Purified proteins were extensively dialysed into PBS.
GST pulldowns were set up using 0.5 mg of either GST or GST
tagged LXR and 20 ml glutathione sepharose beads diluted in 1 ml
GST binding buffer and incubated for 30 mins. 0.5 mg His tagged
Htt 190 was added and the tubes incubated for a further 2 h.
Protein bound to the beads were separated using spin columns to
collect the beads followed by three washes in GST binding buffer
and one wash in PBS then elution in 2X SDS sample buffer.
Zebrafish strain husbandry
Wild type zebrafish of the AB strain were maintained at 28.5uC
under standard conditions in compliance with UK Home Office
regulations. Embryos were collected after natural spawning,
staged as previously described
21 and raised in embryo medium.
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A morphilino, Htt_ATG, was designed to specifically target the
zebrafish huntingtin translation initiation codon (ATG targeting:
59-GCC ATT TTA ACA GAA GCT GTG ATG A- 39 (+5t o
220); obtained from Gene Tools, Philomath, Oregon, USA) and
dissolved in 16Danieau medium (58 mM NaCl, 0.7 mM KCl,
0.4 mM MgSO4, 0.6 mM Ca(NO3), 2, 5 mM HEPES, pH 7.6).
Morpholinos with the same sequence have already been used
and proved to be specific for the downregulation of huntingtin
expression in zebrafish.
22 As a negative control, a mispair control
morpholino with five base modifications out of 25 (Htt_ATG-
5mis: 59-GCg Ata TTA ACA cAA cCT GTc ATG A- 39) was
used and did not produce any phenotype upon injection.
Zebrafish eggs (1–2 cell stage) were injected with 3.5 ng
Htt_ATG morpholino or 3.5 ng corresponding 5 bp mismatch
control (Htt_ATG-5mis) morpholino. At 7 hpf (for cartilage
staining) or 86 hpf (for mRNA expression), half of the injected
embryos were placed in E3 medium (5 mM NaCl, 0.17mM KCl,
0.33 mM CaCl2.2H2O, 0.33 mM MgSO4.7H2O, 5 mM HEPES)
supplemented with 200 nM TO901317 LXR agonist (Tocris,
Bristol, UK) and zebrafish were raised at 28.5uC until 104 hpf.
Zebrafish cartilage staining
After fixation in 4% PFA, 104 hpf zebrafish were stained in
Alcian green (0.1% w/v in 0.37% HCl/70% EtOH) at room
temperature overnight. Zebrafish were washed in 0.37% HCl/
70% EtOH, rehydrated and digested with trypsin for ,4ha t
37uC. Pigment was bleached in 3% H2O2 in 0.5% KOH for
,30 min and fish were stored in 100% glycerol at 4uC. Lower
jaws were dissected using Tungsten needles and photographed
with an Olympus SZX12 microscope at the same magnification.
RESULTS
Huntingtin binds to nuclear receptors
With the aim of identifying new transcriptional pathways
regulated by huntingtin, we tested the following brain
expressed nuclear receptors; LXRa, PPARc, VDR and TRa1
and RXRa for binding to wild-type and mutant huntingtin.
Myc-tagged LXRa, PPARc, VDR, TRa1 and RXRa and FLAG
tagged huntingtin 588 (amino acids 1–588) were expressed in
SK-N-SH cells. The NRs were immunoprecipitated using anti-
Myc antibody and any associated huntingtin was detected by
western blot probed with anti-huntingtin antibody. LXRa,
PPARc, VDR and TRa1 but not RXRa were able to bind to
wild-type huntingtin (fig 1A). Much lower amounts of LXRa,
PPARc, VDR and TRa1 were bound to mutant huntingtin (in
long exposures of blots, fig 1B). Control blots show that similar
amounts of wild-type and mutant huntingtin were expressed
(fig 1D) and that similar amounts of LXRa, VDR, TRa1 and
RXRa were immunoprecipitated (fig 1C). PPARc was expressed
at a lower level in total lysate (data not shown) and therefore less
PPARc is immunoprecipitated relative to the other nuclear
receptors. These data suggest wild-type huntingtin binds to
nuclear receptors to a region conserved between LXRa,P P A R c,
VDR and TRa1 but not RXRa and that mutation of huntingtin’s
polyglutamine tract interferes with this interaction.
Loss of endogenous huntingtin impairs LXR activated
transcription
Recent work describes the disruption of cholesterol homeostasis
in HD.
19 Cholesterol homeostasis is controlled by LXR regula-
tion of transcription, therefore we investigated whether
huntingtin was able to regulate LXR activated transcription.
Wild-type or mutant huntingtin aa1-588 were expressed in
combination with an LXR response element (LXRE) upstream
of a luciferase gene (LXRE-luciferase reporter), or empty
luciferase reporter, LXR and b-galactosidase. Transcriptional
activity from the LXRE-luciferase or empty reporter was
measured following induction by the LXR agonist TO901317.
Wild-type huntingtin significantly increased LXR activated
transcription by 72% but had no effect on an empty luciferase
reporter (fig 2A). Mutant huntingtin had no significant effect
on LXR activated transcription, consistent with its weak LXR
binding ability (fig 2A). In these experiments, huntingtin 588
was expressed at much higher levels than endogenous full
length huntingtin as shown by western blot (fig 2B).
To test whether loss of huntingtin decreased LXR activated
transcription, we studied embryonic stem cells from wild-type
mice or huntingtin knockout mice.
23 An LXRE-luciferase
reporter, LXR and b-galactosidase were transiently expressed
in these cells, transcriptional activity measured using a
luciferase assay and normalised for differences in expression
levels by b-galactosidase assay. In the presence of LXR agonist,
LXR activated transcription was decreased by 64% in huntingtin
knockout cells compared to huntingtin wild-type cells (fig 2C).
Thus, cells expressing normal levels of wild-type full length
huntingtin have higher LXR mediated transcriptional activity,
compared to knockout cells, confirming the physiological
importance of huntingtin in this process.
LXR has been shown to activate transcription of a number of
genes involved in cholesterol metabolism including the ATP
binding cassette transporter 1 gene (ABCA1). The ABCA1
protein mediates the first step of cholesterol reverse transport,
eliminating excess cholesterol from the cell.
24 To determine
whether huntingtin could modulate LXR activated transcrip-
tion of endogenous genes, we performed Q-PCR to assess the
mRNA levels of ABCA1 transcribed following LXR activation
with LXR agonist GW683965 treatment in huntingtin knockout
cells. As expected, ABCA1 mRNA levels were significantly
increased by LXR activation in wild-type cells. This increase was
significantly attenuated in agonist-treated huntingtin knockout
cells to (mean (SEM)) 3.9 (0.7) from 6.2 (1.0) (fold increase over
untreated cells) in agonist treated huntingtin wild-type cells
(Fig. 2D). Similar results were seen with another LXR agonist,
TO901317 (data not shown). LXRa and LXRb gene transcrip-
tion was not significantly different in the two cell lines (data
not shown). These data suggest wild-type huntingtin is able to
act as a co-factor of LXR mediated transcription since over-
expression of huntingtin 588 increases LXR mediated transcrip-
tion of a reporter gene and knockout of huntingtin decreases
LXR mediated transcription of a reporter and a target gene. In
addition, expansion of the polyglutamine tract in mutant
huntingtin leads to loss of Huntington’s co-factor function.
Mapping the huntingtin-LXR regions of interaction
NRs have a conserved domain structure consisting of an N-
terminal activation-function domain (AF-1), a DNA binding
domain (DBD) containing two zinc fingers, a flexible hinge
domain and the ligand binding domain (LBD) whose C-terminal
end also has transcriptional activation function(s).
20 To map the
region(s) of LXR that bind to huntingtin, we made Myc tagged
constructs encompassing the various LXR domains; AF-1 (aa1-
91), AF-1/DBD (aa1-263), DBD (aa92-263), DBD/LBD (aa92-
447) and LBD (aa263-447) and transiently expressed them with
FLAG-tagged huntingtin 588 in SK-N-SH cells. The LXR
domains were immunoprecipitated using anti-Myc antibody
and any associated Htt was detected by western blot probed
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fragments but not the other fragments of LXR, bound strongly
to huntingtin demonstrating that the LBD domain is sufficient
for the interaction with huntingtin to occur (fig 3A).
To dissect the region of huntingtin that was important for its
interaction with LXR, we made FLAG tagged deletion con-
structs of huntingtin;
25 Htt120 (aa1-120), Htt190 (aa1-190) and
Htt315 (aa1-315). We expressed each of these huntingtin
fragments, including Htt588, in combination with Myc-tagged
LXR in COS-7 cells. LXR was immunoprecipitated using anti-
Myc antibody and any associated huntingtin was detected by
western blot probed with anti-FLAG antibody. Htt588 bound
strongly to LXR while Htt190 and Htt315 bound more weakly.
We were unable to detect Htt120 bound to LXR, but this may
be because Htt120 was expressed at lower levels than Htt190,
Htt315 and Htt588 (fig 3B). Therefore, it appears that the entire
1–588 region of huntingtin is necessary for strong binding to
LXR.
We also tested whether these huntingtin fragments could
activate LXR mediated transcription in a similar manner to
Htt588. An LXRE-luciferase reporter, LXR and b-galactosidase
were transiently expressed in HEK cells in combination with
either GFP-HttExon1, FLAG-Htt120, FLAG-Htt190, FLAG-
Htt350 or FLAG-Htt588. Transcriptional activity was measured
using a luciferase assay and normalised for differences in
expression levels by b-galactosidase assay. As previously shown
in fig 3A, Htt588 was able to activate LXR mediated
transcription. However, the other huntingtin fragments,
HttExon1, Htt120, Htt190 and Htt 315, were unable to
significantly alter LXR mediated transcription (fig 3C). Thus,
huntingtin fragments and mutant huntingtin that bind LXR
weakly do not activate LXR mediated transcription.
Our experiments demonstrate that LXR and huntingtin
interact. This interaction may be direct or may be mediated
by another protein or complex of proteins. Therefore, we tested
whether huntingtin could interact directly with LXR. GST
Figure 1 Huntingtin binds to nuclear receptors. Immunoprecipitation of
huntingtin from COS-7 cells transiently expressing pcDNA3.1 Myc-His
empty vector (control) or each of the following Myc tagged receptors;
PPARc, RXRa, LXRa,T R a1 and VDR in combination with either wild-type
or mutant huntingtin 1–588. Representative blots show Myc antibody
immunoprecipitations probed with huntingtin antibody (a short exposure
in panel A and a longer exposure in panel B), Myc antibody
immunoprecipitations probed with Myc antibody (C) and FLAG tagged
huntingtin expressed in total lysate (D).
Figure 2 Huntingtin activates LXR dependent gene transcription. (A)
Activity of an LXRE-luciferase or empty luciferase reporter expressed in
HEK cells in combination with LXR and Htt (wild-type and mutant).
Luciferase activity was normalised to b-galactosidase activity and
compared to empty (no Htt) vector control (mean ¡SEM, n=3
experiments; *p,0.05 as analysed by one way analysis of variance
(ANOVA) with Dunnett’s post test compared to empty vector control).
(B) Western blot showing relative expression of endogenous huntingtin
and transiently expressed huntingtin 1–588 wild-type (WT) and mutant
(Mut) in HEK cells. (C) Activity of an LXRE-luciferase reporter expressed
in Hdh
ex4/5/Hdh
ex4/5 knockout (2/2), and wild-type (+/+) embryonic stem
cells in the presence of the LXR agonist TO901317 (TO). Luciferase
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their in vitro binding tested using a GST pulldown assay. His-
Htt190 was pulled down by GST-LXR but not GST alone,
demonstrating that Htt and LXR can interact directly in vitro
(fig 3D).
We attempted to test whether endogenous LXR in the brain
could interact with endogenous huntingtin. LXR is important
for brain function, and knockout of both LXRa and LXRb
resulted in severe abnormalities of the brain and neurodegenera-
tion.
26 Most areas of the brain have low-medium levels of LXRa
mRNA and medium-high levels of LXRb mRNA
18; however,
LXR protein was barely detectable in the brain (see fig S1A, B in
supplemental material). We also tried to test for an interaction
between the endogenous proteins in several different cell lines
but again LXR was barely detectable (supplemental fig S1B).
LXR is highly expressed in the liver, but unfortunately
huntingtin is poorly expressed in the liver (supplemental fig
S1A). Thus, detection of an endogenous interaction between
LXR and huntingtin has not proved to be possible, as even a
10% interaction would be far below the limits of detection in
our system. It is important to note that we are unaware of
successful endogenous LXR immunoprecipitation to detect
interacting proteins in the literature, presumably due to its
low abundance. Furthermore, the entire literature examining
the effect of LXR interacting proteins on its transcriptional
activity have relied on LXR over-expression experiments to
dissect the interactions and transcriptional effects.
27 28
The huntingtin-LXR interaction is not mediated by pentapeptide
LxxLL motifs present in huntingtin
The LBD of NRs contains a shallow hydrophobic groove that
crystallographic studies have shown to bind a pentapeptide
motif (LxxLL) found in a number of co-activator proteins (NR
binding motif).
29 Huntingtin 588 contains five of these motifs,
two of which share a common leucine. To determine whether
any of these NR binding motifs could mediate the interaction
between huntingtin and the LXR LBD, we made a series of
leucine to alanine point mutations (L211A, L297A, L317A and
L326A). We also made a mutant containing all four point
mutations (quadruple) and a deletion mutation (deletion)
encompassing the entire LxxLL motif-containing region. To
test whether these mutants were still able to bind LXR we
expressed each mutant with or without LXR, immunoprecipi-
tated LXR using a Myc antibody and detected any associated
huntingtin by western blot probed with anti-huntingtin anti-
body. All the mutants were able to bind LXR suggesting that
none of the NR binding motifs were necessary for the
huntingtin-LXR interaction (fig 4A). We also expressed each
of these mutants in combination with an LXRE-luciferase
reporter, LXR and b-galactosidase in HEK cells. Transcriptional
activity was measured using a luciferase assay and normalised
Figure 3 N-terminal huntingtin region 1–588 and ligand binding domain
(LBD) of LXR are necessary for the huntingtin-LXR interaction. (A)
Domains of LXR that bind to huntingtin. Myc-tagged regions of LXR; AF1,
AF1-DNA-binding domain (AF1-DBD), DBD, DBD-ligand binding domain
(DBD-LBD), LBD and full length (FL) were expressed in COS-7 cells in
combination with FLAG-tagged huntingtin 1–588 (middle and bottom
panels, respectively). AF1 was expressed at much lower levels than the
other fragments. Immunoprecipitations were performed with FLAG
antibody and binding proteins were detected by Myc antibody (top
panel). (B) Region of huntingtin that binds to LXR. FLAG tagged regions
of huntingtin: 1–120 (Htt120), 1–190 (Htt190), 1–315 (Htt315), 1–588
(Htt588) were expressed in SK-N-SH cells in combination with Myc-
tagged LXR. Immunoprecipitations were performed with Myc antibody
and binding proteins were detected by FLAG antibody. (C) Activity of an
LXRE-luciferase reporter in HEK cell lysates expressing different
constructs of huntingtin; 1–120 (Htt120), 1–190 (Htt190), 1–315
(Htt315) and 1–588 (Htt588). Luciferase activity was normalised to b-
galactosidase activity and plotted compared to empty vector control
(emp) (mean ¡SEM, n=3 experiments; *p,0.05 as analysed by one
activity was normalised to b-galactosidase activity and plotted
compared to wildtype -TO (mean ¡SEM, n=6 experiments; luciferase
activity in the presence of agonist in 2/2 cells is significantly different
from +/+ cells; *p,0.05 as analysed by one way ANOVA with Dunnett’s
post test). (D) QPCR assessment of expression of ABC-A1 mRNA in
Hdh
ex4/5/Hdh
ex4/5 knockout (2/2) and wild-type (+/+) ES cells following
induction of LXR activity by the LXR agonist GW683965A (GW). cDNA
levels were normalised to GAPDH values and plotted compared to +/+ -
GW (mean ¡SEM, n=4 experiments; ABC-A1 levels in agonist treated
knockout cells are significantly different from agonist treated wild-type
cells; *p,0.05 as analysed by one way ANOVA with Dunnett’s post
test).
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Consistent with the interaction data, all the mutants were able
to activate LXR mediated transcription in a manner similar to
Htt588 (fig 4B). There were no significant differences between
the mutants and wild-type Htt588 as assessed by analysis of
variance (ANOVA). These data suggest that the LxxLL motifs
are not necessary for the huntingtin-LXR interaction or for
activation of LXR mediated transcription.
An LXR agonist partially rescues zebrafish huntingtin knockdown
phenotype
To investigate whether regulation of LXR mediated transcrip-
tion by wild-type huntingtin could play a role in vivo, we tested
whether activation of LXR could rescue development in
huntingtin deficient zebrafish. Blocking translation of hunting-
tin mRNA using ATG specific morpholino oligonucleotides
resulted in severe reduction of cartilage in the lower jaw.
30 Wild-
type zebrafish have seven pharyngeal arches present as
represented diagrammatically in fig 5A,B. In control morpholino
injected, as in wild-type zebrafish, seven pharyngeal arches are
observed (fig 5A). Huntingtin mRNA is expressed in the
cartilage.
30 When huntingtin was knocked down in hunting-
tin-ATG injected zebrafish larvae, only the mandibular and
hyoid arches (P1 and P2) are detectable and they are reduced in
size and wrongly orientated (fig 5C). Either all or the last four of
the five branchial arches are missing and overall staining
intensity is reduced compared to controls, indicating poor
Figure 4 Mutation of nuclear receptor binding motifs in huntingtin has
no effect on transcriptional activation. (A) Immunoprecipitation of Myc-
tagged LXR and (B) activity of an LXRE-luciferase reporter expressed in
SK-N-SH cells or HEK cells, respectively, in combination with individual
Leu to Ala FLAG-huntingtin 1–588 mutants (L211A, L297A, L317A,
L326A), a mutant with all five NR binding motifs mutated (quadruple) or
a deletion mutant missing the region containing the five motifs (deletion).
Figure 5 Effect of an LXR agonist on cartilage of Htt-deficient zebrafish.
(A) Ventral view of an Alcian green stained lower jaw of an Htt_ATG-
5mis control at 102 hpf depicting the normal zebrafish cartilage. A
representative zebrafish is shown from five independent experiments
where 11–22 zebrafish were analysed per experiment. (B) Diagram of the
pharyngeal skeleton in ventral view showing the first or mandibular arch
(P1, white), the second or hyoid arch (P2, dark grey) and five brachial
arches (P3–7, light grey). (C) Cartilage is strongly reduced in Htt_ATG
injected zebrafish. The mandibular (P1) and hyoid (P2) are present but
small and malformed and pharyngeal arches P3–5 are missing. A
representative zebrafish is shown from five independent experiments
where 7–20 zebrafish were analysed per experiment. (D) An LXR agonist
rescues formation (compactation, form, staining intensity) of the anterior
two arches. A representative zebrafish is shown from fove independent
experiments where 9–14 zebrafish were analysed per experiment. (E) Q-
PCR assessment of expression of LXR and LXR target genes mRNA in
uninjected control zebrafish and Htt MO injected zebrafish at 3 dpf. cDNA
levels were normalized to actin levels and were plotted compared to
control zebrafish (mean ¡SEM, n=324 experiments; *p,0.05 as
analysed by one way ANOVA with Dunnett’s post test).
way ANOVA with Dunnett’s post test compared to empty vector control).
(D) GST pulldown of purified His tagged huntingtin 1–190 by GST tagged
LXR. Arrow points to GST-LXR and arrowhead points to GST.
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zebrafish with LXR agonist TO901317 did not significantly
restore the missing branchial arches (fig 5D). However,
intensity of the staining and size of the remaining mandibular
and hyoid arches is visibly increased, indicating rescue of
cartilage formation in huntingtin deficient zebrafish. The LXR
agonist had no effect on control zebrafish.
Only one isoform of LXR is expressed in zebrafish. This
isoform has a higher similarity with mammalian LXRa,
although its ubiquitous expression pattern more closely
resembles LXRb.
31 In zebrafish embryos, LXR is expressed in
the first 24 h following fertilisation suggesting a role for LXR
during development.
31 In adult zebrafish, as in mammalians,
LXR is likely to be involved in regulation of lipid and cholesterol
homeostasis. LXR agonists have been demonstrated to activate
a number of zebrafish LXR target genes involved in these
processes including ATP binding cassette transporter G1
(ABCG1), cytochrome P450 a1 (CYP7A1), fatty acid synthase
(FASN) and acetyl-CoA carboxylase (ACC).
31 We had observed a
partial rescue of a zebrafish huntingtin knockdown phenotype
upon treatment with an LXR agonist and therefore investigated
whether expression of these zebrafish LXR target genes could be
regulated by huntingtin knockdown and subsequent rescue
with LXR agonist. Expression of LXR and LXR target gene
mRNAs were assessed in uninjected control zebrafish and
huntingtin morpholino injected zebrafish treated with and
without LXR agonist. mRNA levels of all four LXR target genes
tested, ABCG1, CYP7A1, FASN and ACC, were significantly
downregulated following knockdown of huntingtin, consistent
with our previous observations that wild-type huntingtin
activates transcription of LXR target genes (fig 5E). Treatment
of huntingtin morpholino injected zebrafish with LXR agonist
TO901317 rescued the downregulation of FASN and ACC but
not the decrease in ABCG1 or CYP7A1 mRNA levels (fig 5E).
These data suggest that huntingtin can regulate the expression
of LXR target genes in vivo. LXR agonist rescue of FASN and
ACC mRNA expression in huntingtin knockdown zebrafish
suggests that huntingtin may regulate these genes through LXR
dependent pathways. However, huntingtin may regulate
ABCG1 and CYP7A1 expression through LXR independent
pathways since treatment with LXR agonist could not rescue
their expression in huntingtin knockdown zebrafish.
DISCUSSION
Huntingtin plays a functional role in regulation of transcription
both in its wild-type and mutant form. Microarray studies in
cell and mouse models of HD and in human HD brains have
revealed widespread dysregulation of transcriptional pathways.
In addition, studies of specific transcription factors have
catalogued a number of transcription factors able to bind to
huntingtin with both dependency and independency on poly-Q
length. These include CA150, CREB, COOH terminal binding
protein, nuclear receptor co-repressor (N-CoR), p53, RNA
polymerase associated protein 30 (RAP30) and Sp1.
5 10–13 32 A
key function of wild-type huntingtin in the modulation of
REST/NRSF transcription has also been described.
16
In this study, we have identified several members of the
nuclear receptor superfamily that are able to interact with
huntingtin. The nuclear receptor superfamily can be divided
into six subfamilies based on the evolution of the two well
conserved domains of NRs, the DBD and LBD.
33 Huntingtin
interactors—LXRa, PPARc, VDR and TRa1—are all members of
subfamily 1 and function as heterodimers with a common
binding partner, RXR. Interestingly, we found RXRa does not
bind to huntingtin. We narrowed down the region of LXR that
binds to huntingtin to be the LBD. Addition of LXR agonist,
however, has no obvious effect on the binding of huntingtin to
LXR as assessed by immunoprecipitation (unpublished data).
The LBD is well conserved between LXRa, PPARc, VDR and
TRa1, the amino acid identity being 30–38%. The amino acid
identity between LXRa and RXRa is less well conserved being
,25%. We also found the LBD of PPARc was able to bind to
huntingtin (data not shown). Based on this finding and the
sequence homology, it is possible that all four nuclear receptors
found to bind to huntingtin interact via their LBDs.
Huntingtin has a multitude of binding partners which cluster
into several different functional groups including cytoskeletal
organisation and biogenesis, signal transduction, synaptic
transmission, proteolysis and regulation of transcription or
translation. Huntingtin’s ability to bind to nuclear receptors
and other transcription factors to regulate transcription of an
even greater number of proteins adds another level of regulation
to huntingtin’s functional capabilities. We find that expansion
of the polyglutamine tract in mutant huntingtin inhibits its
binding to nuclear receptors and its ability to activate LXR
transcription. The mutant protein misfolds resulting in a
conformational change which could block its interaction with
LXR and in turn affect its function. Given huntingtin’s
multiplicity of binding partners with diverse functions, disrup-
tion of its normal function by expansion of the polyglutamine
repeat is likely to have an effect on many cellular processes and
it will be important to understand the relative contributions of
these different processes to the progression of HD.
The LBD of nuclear receptors is required for ligand binding
and receptor dimerisation. LXR/RXR heterodimers bind to
LXREs in the promoter region of target genes to regulate
transcription. In the absence of agonist, the LXR/RXR hetero-
dimer actively inhibits transcription by recruiting co-repressors.
Ligand binding induces dissociation of the co-repressors, leading
to moderate stimulation of transcription, and then allows
recruitment of co-activators causing maximal stimulation of
transcription. We show over-expression of wild-type huntingtin
increases, while knockout of huntingtin reduces LXR mediated
transcription of an LXRE-luciferase reporter. Furthermore,
transcription of the LXR target gene ABCA1 is reduced by
huntingtin knockout. Therefore, we suggest wild-type hunting-
tin acts as a co-factor of LXR mediated transcription. Mutant
huntingtin is unable to activate LXR mediated transcription,
suggesting that expansion of the polyglutamine tract interferes
with normal huntingtin co-factor function.
Recently, huntingtin interacting protein 1 (HIP1) was shown
to modulate transcriptional activity of NRs. HIP1 significantly
repressed transcription when knocked down using a silencing
RNA (siRNA) approach and activated transcription when
overexpressed.
34 Therefore, huntingtin’s co-factor function
could be mediated by HIP1. We tested this hypothesis using a
silencing RNA approach to knockdown HIP1 in HEK cells
transiently expressing LXRE-luciferase reporter, LXR and
huntingtin. HIP1 knockdown had no effect on the huntingtin
activation of LXR mediated transcription, indicating that HIP1
does not mediate huntingtin’s co-factor function (see supple-
mental fig 2).
Many transcriptional co-activators contain multiple, short
LxxLL motifs that adopt a helical structure to bind to a
hydrophobic groove on the surface of the LBD.
29 Huntingtin 588
contains five of these nuclear receptor interaction motifs;
however, mutational analysis demonstrated that they were
not necessary for the huntingtin-LXR interaction, indicating
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motif independent binding has been observed previously for
constitutive coactivator of PPARc which has four LxxLL motifs,
none of which are important for its binding to PPARc.
35 A
number of transcriptional regulators contain glutamine-rich
activating domains that serve as protein–protein interaction
domains.
36 37 Huntingtin also interacts with several transcrip-
tion factors such as p53, RAP30, RAP74 and Sp1 via its amino
terminal proline rich domain.
10 13 Deletion of either of these
domains, however, had no effect on the binding of huntingtin
to LXR (data not shown) suggesting huntingtin binds to LXR
via a novel mechanism. Our data demonstrates in vitro binding
of LXR to huntingtin, shows deletion of different protein–
protein interaction domains of huntingtin (LxxLL motifs,
polyglutamine and polyproline domains) has no effect on co-
factor function, and shows polyglutamine expansion has an
effect on co-factor function, suggesting that huntingtin’s
regulation of transcription is a direct rather than an indirect
effect of huntingtin.
The physiological role of huntingtin’s co-activation of LXR is
unknown. LXRa and b play a central role in the transcriptional
regulation of lipid and cholesterol homeostasis.
38 LXRs act as
sensors, modifying expression of genes in pathways that govern
transport, catabolism and elimination of cholesterol. Knockout
of both LXRa and b led to impaired cholesterol homeostasis and
neuronal degeneration in the brain.
26 Mouse models of HD have
impaired cholesterol biosynthesis.
19 Interestingly, mice over-
expressing wild-type huntingtin with 18 glutamines have a
reversal of this phenotype with a higher activity of the
cholesterol biosynthetic pathway compared to wild-type mice,
suggesting that wild-type huntingtin normally plays a key role
in cholesterol homeostasis. This phenomenon is entirely
compatible with our data where we show a role for wild-type
huntingtin in the modulation of LXR activity. Since alterations
in LXR activity regulate the transcription of cholesterol
excretory genes, wild-type huntingtin could be involved in
regulation of cholesterol homeostasis both at the biosynthetic
and the catabolic level.
Huntingtin is essential for development in mice. Embryos of
huntingtin homozygous knockout mice die by day 8.5.
39 During
development the demand for cholesterol in the brain is
particularly high. In adult brain, a large proportion of the
cholesterol content derives from its accumulation during the
early phases of life. In developing zebrafish, we observed a
severe phenotype, with reduction of cartilage in the lower jaw,
when we knocked down huntingtin. Furthermore, we observed
a decrease in the expression of LXR target genes in huntingtin
knocked down fish. The cartilage phenotype and reduced LXR
target gene expression can be partially rescued by an LXR
agonist, suggesting that huntingtin’s function as a transcrip-
tional co-factor at LXR target genes is important in a
physiological context. It would be interesting to conduct
studies in conditional huntingtin knock-out mice to elucidate
further the in vivo role of huntingtin-LXR interaction and its
biological relevance. Huntingtin interactions with other tran-
scription factors, including other nuclear receptors, are also
likely to be important during development since treatment with
LXR agonist only partially rescued the cartilage phenotype and
did not rescue expression of all the LXR target genes affected by
huntingtin knockdown. Thus, we believe that the rescue of the
FASN and ACC expression in the huntingtin deficient zebrafish
by the LXR agonist suggests that huntingtin may control the
transcription of these genes mainly via LXR. Conversely,
huntingtin may regulate expression of ABCG1 and CYP7A1
via multiple targets and this may explain why they were not
rescued by the LXR agonist in the huntingtin knockdown
zebrafish. In adults, loss of wild-type huntingtin function in HD
and potential disruption of cholesterol homeostasis in the brain
may be important for the progression of HD since cholesterol is
important for synaptogenesis, neurite outgrowth and neuro-
transmitter release, processes which are seen to be impaired in
HD.
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